KR102291310B1 - 트리글리세리드의 고체 조성물 및 이의 용도 - Google Patents

트리글리세리드의 고체 조성물 및 이의 용도 Download PDF

Info

Publication number
KR102291310B1
KR102291310B1 KR1020167013964A KR20167013964A KR102291310B1 KR 102291310 B1 KR102291310 B1 KR 102291310B1 KR 1020167013964 A KR1020167013964 A KR 1020167013964A KR 20167013964 A KR20167013964 A KR 20167013964A KR 102291310 B1 KR102291310 B1 KR 102291310B1
Authority
KR
South Korea
Prior art keywords
less
delete delete
poly
pharmaceutical composition
triheptanoin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167013964A
Other languages
English (en)
Korean (ko)
Other versions
KR20160084407A (ko
Inventor
존 클롭
가브리엘 모리스
에밀 카키스
스티븐 정글스
Original Assignee
울트라제닉스 파마수티컬 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 울트라제닉스 파마수티컬 인코포레이티드 filed Critical 울트라제닉스 파마수티컬 인코포레이티드
Publication of KR20160084407A publication Critical patent/KR20160084407A/ko
Application granted granted Critical
Publication of KR102291310B1 publication Critical patent/KR102291310B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167013964A 2013-11-14 2014-11-14 트리글리세리드의 고체 조성물 및 이의 용도 Active KR102291310B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14
US61/904,369 2013-11-14
PCT/US2014/065693 WO2015073816A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Publications (2)

Publication Number Publication Date
KR20160084407A KR20160084407A (ko) 2016-07-13
KR102291310B1 true KR102291310B1 (ko) 2021-08-23

Family

ID=53058066

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167013964A Active KR102291310B1 (ko) 2013-11-14 2014-11-14 트리글리세리드의 고체 조성물 및 이의 용도

Country Status (18)

Country Link
US (6) US20160243071A1 (enExample)
EP (2) EP3782610A1 (enExample)
JP (4) JP2017501972A (enExample)
KR (1) KR102291310B1 (enExample)
CN (2) CN113181158A (enExample)
AR (2) AR099353A1 (enExample)
AU (1) AU2014348470B2 (enExample)
CA (2) CA2929688C (enExample)
CL (1) CL2016001130A1 (enExample)
ES (1) ES2833294T3 (enExample)
IL (1) IL245588B (enExample)
MX (2) MX383005B (enExample)
MY (1) MY177028A (enExample)
PE (1) PE20161024A1 (enExample)
PH (1) PH12016500821A1 (enExample)
RU (1) RU2016123169A (enExample)
TW (1) TWI640327B (enExample)
WO (1) WO2015073816A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782610A1 (en) * 2013-11-14 2021-02-24 Ultragenyx Pharmaceutical Inc. Solid compositions of triglycerides and uses tehreof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
EP3843716A4 (en) 2018-08-27 2022-06-01 Exerkine Corporation METHODS OF TREATMENT OF LYSOSOMAL STORAGE DISEASES
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004099A1 (en) * 2004-07-02 2006-01-05 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
CN101919453A (zh) 2010-08-16 2010-12-22 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
WO2011159634A1 (en) * 2010-06-14 2011-12-22 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
CA2212047C (en) * 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
CA2361070C (en) * 1999-02-05 2012-04-17 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
WO2004103307A2 (en) * 2003-05-20 2004-12-02 Baylor Research Institute Method of use of five and fifteen carbon fatty acids
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
ATE511838T1 (de) * 2005-03-10 2011-06-15 3M Innovative Properties Co Antimikrobielle zusammensetzungen mit hydroxycarboxylsäureestern
US8476319B2 (en) * 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
CN101484148A (zh) * 2006-02-10 2009-07-15 斯博茨科姆丹麦私人有限公司 包衣片剂及其制备方法和相关用途
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
PL2760479T3 (pl) 2011-09-30 2017-09-29 Horizon Therapeutics, Llc Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
WO2013158616A1 (en) * 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency
MX373650B (es) 2012-12-13 2020-03-31 Baylor Res Institute At Dallas Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1.
EP3782610A1 (en) * 2013-11-14 2021-02-24 Ultragenyx Pharmaceutical Inc. Solid compositions of triglycerides and uses tehreof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004099A1 (en) * 2004-07-02 2006-01-05 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
WO2011159634A1 (en) * 2010-06-14 2011-12-22 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
CN101919453A (zh) 2010-08-16 2010-12-22 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法

Also Published As

Publication number Publication date
CA2929688C (en) 2023-06-13
EP3068383A1 (en) 2016-09-21
RU2016123169A (ru) 2017-12-19
AU2014348470B2 (en) 2020-01-30
JP2024129109A (ja) 2024-09-26
PH12016500821A1 (en) 2016-06-13
WO2015073816A1 (en) 2015-05-21
US20250120934A1 (en) 2025-04-17
EP3068383A4 (en) 2017-11-08
ES2833294T3 (es) 2021-06-14
MX2016006329A (es) 2016-09-06
JP2020111585A (ja) 2020-07-27
TW201609189A (zh) 2016-03-16
MX2021001790A (es) 2021-04-19
US20200069631A1 (en) 2020-03-05
MX383005B (es) 2025-03-13
AR099353A1 (es) 2016-07-20
IL245588A0 (en) 2016-06-30
TWI640327B (zh) 2018-11-11
JP2022107017A (ja) 2022-07-20
CA2929688A1 (en) 2015-05-21
PE20161024A1 (es) 2016-11-10
CN105764497A (zh) 2016-07-13
MY177028A (en) 2020-09-02
JP2017501972A (ja) 2017-01-19
US20250120936A1 (en) 2025-04-17
US20250120935A1 (en) 2025-04-17
EP3068383B1 (en) 2020-09-16
US20160243071A1 (en) 2016-08-25
CN113181158A (zh) 2021-07-30
AR130666A2 (es) 2025-01-08
CA3197154A1 (en) 2015-05-21
KR20160084407A (ko) 2016-07-13
CL2016001130A1 (es) 2017-01-20
IL245588B (en) 2021-08-31
EP3782610A1 (en) 2021-02-24
AU2014348470A1 (en) 2016-05-26
US20230181513A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US20250120934A1 (en) Compositions of triglycerides and uses thereof
JP3382940B2 (ja) 中枢ドパミン欠乏状態を治療するための経口投与可能な医薬製剤
CA2231342C (fr) Composition pharmaceutique pour administration par voie orale
CN103889455B (zh) 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂
CN105025886A (zh) 地拉罗司(deferasirox)的口服制剂
WO2010143052A1 (en) Novel pharmaceutical compositions containing pregabalin
WO2009000132A1 (fr) Formulation effervescente à libération immédiate et procédé de préparation de celle-ci
RU2493843C2 (ru) Содержащие ацеклофенак пероральные лекарственные средства с контролируемым высвобождением и способ их изготовления
US11318090B1 (en) In situ gelling composition as a pH-selective and mucoadhesive sustained release drug delivery system
HK40056892A (en) Solid compositions of triglycerides and uses thereof
RU2476208C2 (ru) Стабильная фармацевтическая композиция водорастворимой соли винорелбина
CN105596304B (zh) 用于减缓周边血管疾病病患间歇性跛行症状的属喹啉酮衍生物的西洛他唑的新颖调配物
BR112016010583B1 (pt) Composição, composição farmacêutica e uso das mesmas
TW202541789A (zh) （ｚ）－因多昔芬（ｅｎｄｏｘｉｆｅｎ）之口服調配物及其使用方法
JP2018519345A (ja) 直腸の炎症性変化の治療用医薬製剤
CN114599347A (zh) 治疗肾上腺皮质癌与库欣综合征的口服施用的包含米托坦的药物组合物
CN105168155A (zh) 可直接压制的丙酸衍生物颗粒

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5